Parkure was one of the 10 shortlisted companies selected to pitch in the Health category at the finals which took place in Manchester on the June 13th and 14th, 2017. The competition was fierce, with 40 shortlisted entries in 4 categories including exciting start-up companies, as well as spin-outs from the University of Cambridge, the University of Edinburgh, Lund University, ETH Zürich and Imperial College London. Except the cash prize, Parkure will receive tailored business advice and mentoring from KPMG and Mewburn Ellis LLP.
The Emerging Technologies Competition is the RSC’s annual innovation initiative, turning promising ideas into commercial reality. Now in its fifth year, the competition brings cutting edge science to the real world for the benefit of society.
With over 54,000 members and an international publishing and knowledge business, the RSC is the UK’s professional body for chemical scientists, supporting and representing members and bringing together chemical scientists from all over the world.
May 24, 2017
by Lysimachos Zografos Comments Off on Parkure’s pipeline news: two drugs pre-clicanically validated.
Two key pipeline compounds discovered by Parkure have been pre-clinically validated as part of a collaboration with Charles River Laboratories. Both drugs were found to rescue the symptoms of a virally induced rat model of Parkinson’s disease.
Beyond the progress for Parkure’s pipeline the results are indicative of the translational power of Parkure’s platform and it’s ability to discover drugs that act on validated Parkinson’s disease drug targets. The two drugs in question are repurposed but Parkure has already synthesised and tested novel chemical derivatives with very encouraging results.
April 21, 2017
by Lysimachos Zografos Comments Off on New paper out
We are committed to Parkinson’s research and our new paper on repurposing Astemizole and Ketoconazole is out (and free to access until May the 5th).
Abstract: Parkinson’s disease is a growing threat to an ever-ageing population. Despite progress in our understanding of the molecular and cellular mechanisms underlying the disease, all therapeutics currently available only act to improve symptoms and do not stop the disease process. It is therefore imperative that more effective drug discovery methods and approaches are developed, validated, and used for the discovery of disease-modifying treatments for Parkinson’s. Drug repurposing has been recognized as being equally as promising as de novo drug discovery in the field of neurodegeneration and Parkinson’s disease specifically. In this work, we utilize a transgenic Drosophila model of Parkinson’s disease, made by expressing human alpha-synuclein in the Drosophila brain, to validate two repurposed compounds: astemizole and ketoconazole. Both have been computationally predicted to have an ameliorative effect on Parkinson’s disease, but neither had been tested using an in vivo model of the disease.After treating the flies in parallel, results showed that both drugs rescue the motor phenotype that is developed by the Drosophila model with age, but only ketoconazole treatment reversed the increased dopaminergic neuron death also observed in these models, which is a hallmark of Parkinson’s disease. In addition to validating the predicted improvement in Parkinson’s disease symptoms for both drugs and revealing the potential neuroprotective activity of ketoconazole, these results highlight the value of Drosophila models of Parkinson’s disease as key tools in the context of in vivo drug discovery, drug repurposing, and prioritization of hits, especially when coupled with computational predictions.
April 11, 2017
by Lysimachos Zografos Comments Off on Parkure at biotrinity 2017 London
Parkure will be one of the selected companies presenting at biotrinity 2017 in London. If you are attending the meeting you can catch our presentation on Wednesday April 10th at 10:10 (early stage therapeutics track).
June 30, 2016
by Lysimachos Zografos Comments Off on Parkure secures Innovation Voucher
We are happy to officially announce that Parkure successfully raised an investment from Deepbride Capital LLP ( (DBC). DBC’s team includes experienced professionals in the field of Life Sciences and Technology. DBC will work closely with the management at Parkure to ensure we can make the best use of the resources, experience and conne
June 30, 2016
by Lysimachos Zografos Comments Off on Life is people
Our friend Simon shared this great video that his daughter Eliza produced. Working on drug discovery means that we have to deal with how nasty Parkinson’s is at the molecular and medical level on a daily basis. Watching this reminded us that the human side always prevails.
June 23, 2015
by Lysimachos Zografos Comments Off on Parkure featured at Business Quarterly
The Royal Society of Edinburgh (RSE) is Scotland’s national academy of science and letters. As part of their invaluable support to Scottish Life Sciences they offer Enterprise Fellowships in order to enable promising science and technology researchers to grow into successful entrepreneurs.
We are delighted to announce that Parkure’s CEO, Dr. Lysimachos Zografos was awarded the RSE Enterprise Fellowship in order to pursuit the successful development of the company. The fellowship offers financial support as well as training, mentoring and access to networks of influential individuals.